Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Menopause | D008593 | EFO_0003922 | N95 | 6 | 4 | 4 | 7 | 2 | 23 |
Postmenopause | D017698 | — | — | 8 | 5 | 3 | 2 | 3 | 21 |
Atrophy | D001284 | — | — | 2 | — | 5 | 1 | 2 | 10 |
Carcinoma | D002277 | — | C80.0 | 1 | 6 | 1 | 1 | — | 9 |
Atrophic vaginitis | D059268 | EFO_1001271 | — | 2 | — | 3 | 3 | 1 | 9 |
Vaginitis | D014627 | EFO_0005757 | N76 | 3 | — | 1 | 3 | 2 | 9 |
Hot flashes | D019584 | — | — | — | — | 4 | 2 | 2 | 8 |
Pelvic organ prolapse | D056887 | EFO_0004710 | — | — | — | 1 | 4 | 1 | 6 |
Prolapse | D011391 | — | — | — | — | 1 | 4 | 1 | 6 |
Hyperplasia | D006965 | EFO_0000536 | — | — | 2 | 2 | 1 | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 3 | 19 | 13 | — | 3 | 34 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 5 | 9 | 2 | — | 4 | 19 |
Adenocarcinoma | D000230 | — | — | 1 | 8 | 2 | — | — | 11 |
Osteoporosis | D010024 | EFO_0003882 | M81.0 | 1 | — | 6 | — | 2 | 9 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 2 | 5 | — | — | 6 |
Neoplasms | D009369 | — | C80 | — | 3 | 1 | — | — | 4 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 2 | 3 | — | — | 4 |
Coronary disease | D003327 | — | — | — | 1 | 4 | — | — | 4 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | 4 | — | — | 4 |
Coronary artery disease | D003324 | — | I25.1 | — | 1 | 3 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Triple negative breast neoplasms | D064726 | — | — | 1 | 4 | — | — | — | 4 |
Male breast neoplasms | D018567 | — | — | — | 2 | — | — | 1 | 3 |
Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 2 | — | — | — | 2 |
Lymphatic metastasis | D008207 | EFO_1001364 | — | — | 1 | — | — | — | 1 |
Risk reduction behavior | D040242 | — | — | — | 1 | — | — | — | 1 |
Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | — | — | — | 1 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
Sclerosis | D012598 | — | — | — | 1 | — | — | — | 1 |
Carcinoma in situ | D002278 | — | D09.9 | — | 1 | — | — | — | 1 |
Breast carcinoma in situ | D000071960 | — | D05 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 6 | — | — | — | — | 6 |
Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 1 | — | — | — | 1 | 2 |
Estrogen replacement therapy | D015914 | — | — | 2 | — | — | — | — | 2 |
Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | 1 | — | — | — | 1 | 2 |
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | — | — | — | — | 1 |
Sleep | D012890 | GO_0030431 | — | 1 | — | — | — | — | 1 |
Metrorrhagia | D008796 | — | N92.1 | 1 | — | — | — | — | 1 |
Premature menopause | D008594 | — | E28.31 | 1 | — | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 1 | 1 |
Postoperative pain | D010149 | — | G89.18 | — | — | — | — | 1 | 1 |
Gender dysphoria | D000068116 | — | F64 | — | — | — | — | 1 | 1 |
Breast density | D000071060 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Estrogens conjugated |
INN | — |
Description | Conjugated estrogens (CEs), or conjugated equine estrogens (CEEs), sold under the brand name Premarin among others, is an estrogen medication which is used in menopausal hormone therapy and for various other indications. It is a mixture of the sodium salts of estrogen conjugates found in horses, such as estrone sulfate and equilin sulfate. CEEs are available in the form of both natural preparations manufactured from the urine of pregnant mares and fully synthetic replications of the natural preparations. They are formulated both alone and in combination with progestins such as medroxyprogesterone acetate. CEEs are usually taken by mouth, but can also be given by application to the skin or vagina as a cream or by injection into a blood vessel or muscle.
|
Classification | Unknown |
Drug class | estrogens |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 12126-59-9 |
RxCUI | — |
ChEMBL ID | CHEMBL1201649 |
ChEBI ID | — |
PubChem CID | 656613 |
DrugBank | DB00286 |
UNII ID | — |